Adam J. Luginbuhl

Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (17)

Year:

2026

Figure s4. Gene set enrichment analysis (GSEA) across baseline responder vs. nonresponder comparisons and baseline vs. post-treatment analyses in the durvalumab-metformin clinical trial and other clinical trial cohorts. GSEA was performed to assess differences between baseline responders and nonresponders, as well as baseline vs. post-treatment samples

Year:

2025

Purpose: Immune checkpoint inhibitors (ICI) have demonstrated clinical benefit in head and neck squamous cell carcinoma (HNSCC); however, single-agent efficacy is limited, leaving significant unmet needs. Metformin may synergize with ICIs, offering promise to improve response rates. We leveraged multiomic data from a randomized, presurgical neoadjuvant trial (NCT03618654) evaluating a single infusion of the anti–PD-L1 ICI durvalumab with or without daily, standard dose metformin in previously untreated, nondiabetic patients with HNSCC to understand predictors of response and the effect of combination therapy. Patients and Methods: Clinical, pathologic, and correlative data were analyzed to investigate response and resistance mechanisms. We present an in-depth multiomic analysis of primary tumor specimens to study treatment response/resistance in human papillomavirus–positive HNSCC. Results: Baseline samples revealed that myofibroblastic cancer-associated fibroblast and extracellular matrix signatures were enriched in durvalumab plus metformin nonresponders, which were localized to the leading tumor edge on spatial transcriptomics. In contrast, baseline responder samples were enriched for the Langerhans-like dendritic cell (DC) state and IFN signatures. Treatment increased intratumoral CD8 + T-cell and IFN signatures and peripheral blood CCL2 levels. Responders demonstrated macrophage and DC enrichment and antigen processing and presentation upregulation. Enrichment of cell cycle–related gene sets, specifically the MYC targets V1 hallmark gene set, correlated with nonresponse. Conclusions: Early response and resistance dynamics for durvalumab plus metformin in human papillomavirus–positive HNSCC reveal baseline extracellular matrix–myofibroblastic cancer-associated fibroblast as predictive of nonresponse. In contrast, responders were distinguished by baseline enrichment in the Langerhans-like DC state and posttreatment antigen-presenting gene sets.

Year:

2025

Figure s5. Baseline immune cell composition in responders and nonresponders across bulk, tumor, and stromal compartments & Immune cell deconvolution analysis in bulk tumor samples of responders and nonresponders before and after durvalumab-metformin treatment.

Year:

2025

Figure s11. Carcinoma ecotype differences at baseline and after treatment in HPV+ HNSCC responders and non-responders. This figure illustrates differences in carcinoma ecotype composition before and after treatment in HPV+ HNSCC patients

Year:

2025

Supplement Figure 3: Signature-based Biomarkers. A: Signature-Based biomarkers for HPV negative patients. B: Signature-based biomarkers for HPV positive patients. ‘Primary Path Response’ refers to analysis based on the pTR at the primary site alone. ‘Overall path response’ refers to analysis based on primary + lymph node response.

Year:

2025

Supplement Figure 1: Waterfall Plots. A: Degree of pathologic treatment response (pTR) at the lymph nodes. B: Degree of pathologic response at the primary site, stratifed by treatment arm. C: Degree of RECIST response of primary tumor site (yellow) and lymph nodes (purple), stratifed by treatment arm.

Year:

2025

Supplement Table 4A-4B: The following is a comprehensive list of the top 20 functional enrichments in the B cell (A) and CAF2 (B) gene sets utilizing STRING database to analyze protein-protein interaction pairs among the leading edge.

Year:

2025

Supplement Table 2A-2E: GSEA quantitative data for the B cell gene sets and CAF2 gene set for Post- vs Pre-treatments Responders vs Non responders. The following is a comprehensive list of supervised B-cell (A-C) and CAF (D-E) enrichment scores, normal enrichment scores, p-values, and q-values for the included gene sets.

Year:

2025

Supplementary Figure 2: Effect of IDO inhibitor BMS986205 on response rate and the tryptophan kynurenine pathway. A and B: IDO1 gene expression levels and tryptophan kynurenine pathway activity score, respectively, compared between baseline samples of responders (R) and non-responders (NR) on nivolumab + BMS986205 and nivolumab-only therapies. C: Tryptophan kynurenine pathway activity score compared between baseline and post-treatment samples of R and NR on nivolumab + BMS986205 and nivolumab-only therapies. - ns, *p

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2025

Year:

2022

Collaborators (19)

Andrew South

Oros Family Professor in Rare Skin Diseases

University of Wisconsin-Madison

UNITED STATES
View details

Megan Roche

Thomas Jefferson University

UNITED STATES
View details

Ramkrishna Mitra

Assistant Professor

Thomas Jefferson University

UNITED STATES
View details

Nolan B. Seim

Assistant Professor

Ohio State University

UNITED STATES
View details

David Cognetti

department of surgery thomas jefferson university hospital sidney kimmel medical college philadelphia university and tho

UNITED STATES
View details

Joseph Curry

Associate Professor

Thomas Jefferson University Hospital

UNITED STATES
View details

Tingting Zhan

Associate Professor

Thomas Jefferson University

UNITED STATES
View details

Rita Axelrod

Professor

Thomas Jefferson University

UNITED STATES
View details

George Prendergast

Professor, President & CEO

Lankenau Institute for Medical Research

UNITED STATES
View details

Hushan Yang

Professor

Thomas Jefferson University

UNITED STATES
View details

Benjamin Leiby

Professor

Thomas Jefferson University

UNITED STATES
View details

Charalambos Solomides

Professor

Thomas Jefferson University

UNITED STATES
View details

Rajanikanth Vadigepalli

Thomas Jefferson University

UNITED STATES
View details

Scott W. Keith

Thomas Jefferson University

UNITED STATES
View details

Larry Harshyne

Associate Professor

Thomas Jefferson University

UNITED STATES
View details

Jennifer M. Johnson

Thomas Jefferson University

UNITED STATES
View details

John R. Eisenbrey

Thomas Jefferson University

UNITED STATES
View details

Ubaldo Martinez-Outschoorn

Associate Professor

Thomas Jefferson University

UNITED STATES
View details

Stacey Gargano

Thomas Jefferson University Hospital

UNITED STATES
View details